By Benjamin Chiou
Date: Monday 05 Jan 2026
(Sharecast News) - Pharma giant GSK has received regulatory approval in China for its Nucala treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD).
| Director Declaration | 02-Jan-2026 | ShareCast |
| Total Voting Rights | 02-Jan-2026 | ShareCast |
| Total Voting Rights | 02-Jan-2026 | ShareCast |
| Transaction in Own Shares | 02-Jan-2026 | ShareCast |
| Completion of Sale of Diagnostics Distributor | 02-Jan-2026 | ShareCast |
| Form 8.3 - NCC Group plc | 05-Jan-2026 | 12:03 | RNS |
| Form 8.5 (EPT/RI) NCC Group PLC | 05-Jan-2026 | 12:00 | RNS |
| Form 8.3 NCC Group Plc | 05-Jan-2026 | 11:11 | RNS |
| Nucala for adults with COPD approved in China | 05-Jan-2026 | 07:00 | RNS |
| Transaction in Own Shares | 05-Jan-2026 | 07:00 | RNS |
| Questor:Meggitt | 23-Dec-2014 | Telegraph |
| Questor :KCOM | 27-Nov-2014 | Telegraph |
| Questor :Ricardo | 31-Oct-2014 | Telegraph |
| Questor:CSR | 17-Oct-2014 | Telegraph |
| Questor:BAE Systems | 03-Sep-2014 | Telegraph |
| Price | 5,635.17 |
| Change Today | 23.98 |
| % Change | 0.43 % |
| 02-Jan-26 Close | 5,611.19 |
You are here: research